Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study

Trial Profile

Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluorouracil (Primary) ; Imiquimod (Primary) ; Ingenol mebutate (Primary) ; Methyl aminolevulinate (Primary)
  • Indications Actinic keratosis
  • Focus Therapeutic Use
  • Acronyms Akti

Most Recent Events

  • 12 Jan 2020 Results assessing a trial-based cost-effectiveness analysis of topical 5-fluorouracil vs imiquimod vs ingenol mebutate vs methylaminolevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area published in the British Journal of Dermatology
  • 16 Sep 2019 Results published in the British Journal of Dermatology.
  • 28 Sep 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top